Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Am J Med Sci. 2012 Jun;343(6):446-51. doi: 10.1097/MAJ.0b013e318239c96c.
Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids.
Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects' surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function.
BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates.
These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS.
分泌型磷脂酶 A2(sPLA2)可水解细胞膜和肺表面活性剂等细胞外结构中的磷脂。本研究旨在验证以下假说,即在急性呼吸窘迫综合征(ARDS)期间,sPLA2 在人肺中升高,并且 sPLA2 水平与通过水解表面活性剂磷脂导致的表面活性剂损伤有关。
从 18 例早期 ARDS(<72 小时)患者的支气管肺泡灌洗液(BAL)中获得样本,并与 10 例健康志愿者的样本进行比较。联合测定 ARDS 患者的表面活性剂异常,包括表面活性剂磷脂组成、大、小聚集体分布和表面张力功能,来测量分泌型磷脂酶 A2 水平(酶活性和酶免疫测定)。
与健康受试者相比,通过体外水解磷脂酰甘油(PG)和磷脂酰胆碱(PC),ARDS 样本中的 BAL sPLA2 酶活性明显升高。酶免疫测定确定 ARDS BAL 液中 PLA2G2A 蛋白增加,与 sPLA2 对 PG 的酶活性强烈相关。特别有趣的是,作者证明了 ARDS 样本中较大聚集体的 PG 平均耗竭了 69%,而正常对照则无此现象。此外,PG 和 PC 的 sPLA2 酶活性与 BAL 中 PG 和 PC 的体内回收率分别相关,并且与大、小表面活性剂聚集体的改变分布相关。
这些结果支持以下假说,即 sPLA2 介导的表面活性剂磷脂水解,特别是 PLA2G2A 对 PG 的水解,导致早期 ARDS 中表面活性剂损伤。